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Guest Editorial
Atrial Fibrillation Screening in Hong Kong − Where Are We Now?
NGAI-YIN CHAN
Deputy Chief-of-Service, Department of Medicine & Geriatrics, Princess Margaret Hospital, Hong Kong

Atrial fibrillation (AF) is the most common
sustained heart rhythm disorder1 and has become a
global epidemic especially in the developed countries
with aging population. Although the risk of AF-related
stroke can be markedly reduced by 64-70% by oral
anticoagulation therapy,2 a major challenge remains to
be the evasive nature of the condition to be diagnosed
early for effective treatment. Around a quarter of patients
have silent or asymptomatic AF3 and up to 25% of
patients with AF-related stroke have AF diagnosed only
at the time of stroke.3-5
According to the WHO criteria, a disease is
suitable for screening when it is an important health
problem with an accepted treatment, there are facilities
for diagnosis and treatment, there is a latent and
symptomatic stage, the natural history is understood,
there is an agreed policy on whom to treat, the cost of
finding is economically balanced with overall health,
the case finding is a continuous process and the
screening test is suitable and acceptable to the
population.6 AF satisfies most of those criteria and
currently the European Society of Cardiology
recommends opportunistic screening for AF by pulse
taking or electrocardiogram rhythm strip in patients over
65 years of age.2 Screening for AF in different settings
and with different tools have been studied7 and in recent
few years, researchers in Hong Kong have contributed
significantly to the knowledge base in this area.
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There were 2 large-scale community-based
systematic screening programs carried out in Hong Kong
in recent years.8,9 In both studies, Kardia mobile device,
capable of producing a single-lead wireless smartphone
electrocardiogram (sECG) for 30 seconds was used as
the tool for screening.10 Chan et al reported a study
aiming to assess the feasibility of community screening
for AF using sECG and to generate epidemiological data
on the prevalence and risk factors of AF in Hong Kong.8
All citizens aged 18 or above were eligible for
participation. Among 13,122 (mean age 64.7) citizens,
101 (0.8%) had newly diagnosed AF with 66 (65.3%)
being asymptomatic. The mean CHA2DS2VASc score
was 3.1 in patients with newly diagnosed AF. The
number-needed-to-screen (NNS) for one newly
diagnosed AF was 129. AF was detected with sECG in
239 (1.8%) citizens and it was likely persistent AF. Apart
from those patients, 872 (6.6%) citizens self-reported
history of AF without sECG showing it and this likely
represents paroxysmal AF. The independent predictors
of AF shown in this study included increasing age and
height, history of heart failure, valvular heart disease,
stroke, hyperlipidaemia, coronary artery disease,
peripheral artery disease and cardiothoracic surgery.
Chan et al further examined the effectiveness of another
community-based AF screening program named the
AFinder program, the results of which were recently
presented in a late-breaking session of the European
Society of Cardiology Congress 2017.9 The AFinder
program was characterized by being initiated by a panel
of cardiologists, led by the Hong Kong Council of Social
Service which was a non-governmental organization,
and carried out by a group of trained layperson
volunteers. All citizens aged 50 or above were eligible
for participation. Among 10,735 (mean age 78.6)
citizens screened with interpretable sECG's, 244 (2.3%)
had AF and 74 (0.69%) had newly diagnosed AF. The
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mean CHA2DS2VASc score was 3.9 in patients with
newly diagnosed AF. The NNS for one newly diagnosed
AF was 145. A nurse performed a 9-month phone
follow-up on those patients with AF and assessed the
health-seeking behavior of them and for those indicated,
whether they were given oral anticoagulation and their
compliance. Among 72 patients with newly diagnosed
AF and indication for oral anticoagulation, only 47
(65%) of them sought medical attention and more
disappointingly, only 17 (24%) of them were prescribed
oral anticoagulation. Once they were given oral
anticoagulation, most of them (16, 94%) reported 100%
compliance to therapy. Compared with the NNS for one
newly diagnosed AF, the NNS for one patient receiving
appropriate oral anticoagulation for newly diagnosed
AF increased 3.6-fold to 671. This seriously underscores
the utmost importance of a more structured downstream
management pathway being embedded in any AF
screening program. The potential of Kardia mobile
device for auto-screening for AF has also been assessed
in this study. The sensitivity and specificity of the
automated algorithm in diagnosing AF were 75% and
98.2% respectively. The positive predictive value and
negative predictive value were 64.9% and 99.5%
respectively. The suboptimal sensitivity of the current
version of algorithm limits its application in autoscreening.
Screening for AF has also been studied in the
primary care setting in Hong Kong and different tools
have been used.11,12 Chan and Siu et al used a smartphone
camera-based device capable of diagnosing AF by
measuring photoplethysmographic pulse waveform for
AF screening in a primary care setting.11 Patients with
hypertension and/or diabetes mellitus or were ≥65 years
of age were screened. AF was found in 28 (2.76%) of
1,013 participants and 5 (0.5%) had newly diagnosed
AF. The sensitivity and specificity of the automated
algorithm of the device were 92.9% and 97.7%
respectively. The positive and negative predictive value
were 53.1% and 99.8% respectively. The same group
of researchers reported the use of another device, an
automated blood pressure measurement device which
is capable of generating an irregularity index based on
R-R intervals, for AF screening, again in the primary
care setting.12 Similar to the study described above, they
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screened patients with hypertension and/or diabetes
mellitus or who were ≥65 years of age. In 5,969 patients
recruited, AF was diagnosed in 72 (1.2%) of them. The
proportion of patients with newly diagnosed AF was
however not mentioned. The sensitivity and specificity
of this device in diagnosing AF were 80.6% and 98.7%
respectively. The positive and negative predictive value
were 42.4% and 99.8% respectively. The overall
diagnostic performance as determined by area under
curve was 0.90.
AF screening program has also been carried out
in specialist medical outpatient clinic in Hong Kong.13
Yan et al screened 9,046 (mean age 72.1) patients with
the Kardia mobile device and identified 121 (1.5%)
patients with newly diagnosed AF, all of whom had
CHA 2DS 2VASc score ≥2. In addition, the overall
prevalence of AF was 9.4% (850/9,046) in this screened
population.
Although increasing data has become available
in AF screening in recent years, the questions on what
the most appropriate setting is and what the best tool
should be remain. Obviously, many of us are looking
forward to large and appropriately-powered randomized
outcome studies to answer the above questions and in
addition, to confirm that systematic AF screening
programs can indeed reduce the burden of stroke and
the consequent mortality. In Hong Kong, different
groups of researchers studied AF screening in different
settings and with different tools. However, they have
the same passion and vision of reducing the burden of
stroke and the consequent disability and deaths in Hong
Kong. For any AF screening program to be sustainable,
it is essential, at some point in time, to seek support
from the government. In Hong Kong, we are now
probably at that critical juncture.
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